Laryngeal Cancer
A malignant tumor of the voice box (larynx), most commonly squamous cell carcinoma, strongly linked to smoking and presenting early with hoarseness.
Emergency Management: Acute airway obstruction requiring an emergency awake tracheostomy. Massive hemoptysis requiring airway protection.
Laryngeal cancer is a malignant neoplastic disease primarily arising from the squamous epithelium of the laryngeal mucosa. It most commonly affects the glottis (true vocal cords) but can also originate in the supraglottis or subglottis. The disease is heavily associated with tobacco and alcohol consumption.
Detailed Overview
Laryngeal cancer is the most common malignancy of the head and neck, typically presenting as squamous cell carcinoma (SCC) in over 90% of cases. The exact location of the tumor determines the clinical presentation, lymphatic spread potential, and treatment approach. Glottic cancers typically present early with hoarseness and have poor lymphatic drainage, leading to lower rates of early nodal metastasis. Conversely, supraglottic tumors have rich lymphatic drainage, often presenting later with nodal involvement. Treatment requires a multidisciplinary approach balancing oncological cure with voice, swallowing, and airway preservation.
Epidemiology & Demographics
Incidence is approximately 3 per 100,000 annually. It predominantly affects males with a male-to-female ratio of 4:1. Peak incidence occurs in the 6th and 7th decades of life (ages 55-70). African Americans have a higher incidence and lower survival rates compared to Caucasians.
Etiological Mechanism
The primary etiology involves genetic mutations (e.g., TP53, CDKN2A) triggered by prolonged exposure to carcinogens. Human papillomavirus (HPV), particularly HPV-16, plays a role in a minority of cases, especially in non-smokers.
Primary Causes
Primary causes are DNA damage from tobacco smoke (polycyclic aromatic hydrocarbons) and alcohol (acetaldehyde). Synergistic effects occur when both are used.
Carcinogens in tobacco and alcohol induce progressive genetic and epigenetic alterations in laryngeal epithelial cells. This sequence progresses from normal squamous epithelium to hyperplasia, dysplasia, carcinoma in situ (CIS), and finally invasive squamous cell carcinoma. Mutations in the p53 tumor suppressor gene are early and frequent events. Tumor invasion disrupts normal laryngeal anatomy, affecting vocal cord mobility and airway patency, while facilitating metastasis through regional cervical lymphatics.
Diagnostic Criteria & Guidelines
Definitive diagnosis requires direct visualization via flexible or rigid laryngoscopy followed by a tissue biopsy confirming invasive squamous cell carcinoma. Staging requires contrast-enhanced CT or MRI of the neck.
For early-stage (I-II): Radiation Therapy (60-70 Gy over 6-7 weeks) or Endoscopic Surgery. For advanced stage (III-IV): Concurrent chemoradiation with Cisplatin 100 mg/m2 IV every 3 weeks for 3 doses + definitive RT (70 Gy).
Second-Line & Adjunctive Therapy
Salvage total laryngectomy with bilateral neck dissection. For recurrent/metastatic disease: Pembrolizumab 200 mg IV every 3 weeks +/- Platinum/5-FU chemotherapy.
Surgical & Procedural Management
Procedures range from transoral laser microsurgery (TLM) for early disease to Total Laryngectomy with placement of a tracheoesophageal puncture (TEP) prosthesis for voice rehabilitation.
Patient Counseling & Advice
Discuss the permanent nature of a stoma if total laryngectomy is required. Explain the acute side effects of radiation, including severe sore throat (mucositis) and dry mouth (xerostomia).
Follow-Up & Monitoring Schedule
Physical exam with flexible laryngoscopy every 1-3 months for year 1, every 2-6 months for year 2, every 4-8 months for years 3-5, then annually.
Preventive Strategies
Primary prevention involves avoidance of tobacco and excessive alcohol. HPV vaccination is recommended.
5-year survival for Stage I glottic cancer is ~90%. Stage III/IV 5-year survival drops to 40-50%.